Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France

Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real-world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry. A total of 1451 adults with histologically confirmed DDLPS diagnosed between 2010 and 2021 across 14 expert centers were included. The median age at diagnosis was 67 years, with a male predominance (M/F ratio 1.84). The retroperitoneum was the most frequent site (51.6%), and tumors were large (median 150 mm) and FNCLCC Grade 2-3 in 82.6%. MDM2 amplification was confirmed in 97.4% of tested cases. Surgery was performed in 91% of localized cases and was the strongest independent prognostic factor for overall survival (OS). After a median follow-up of 78.4 months, median OS was 90.3 months (95% CI 82.7-101.0). Among metastatic patients, the median first-line progression-free survival (PFS1) was 4.1 months, and second-line PFS (PFS2) was 3.1 months, with stable disease as the most common best response (40.6%) and 12% of partial response. Doxorubicin-based chemotherapy remained the predominant systemic treatment but yielded only modest activity, with no difference compared to other regimens in terms of response rate. Independent predictors of improved OS included younger age, smaller tumor size, good performance status, lower grade and absence of metastasis at diagnosis. This large, population-based study provides the most comprehensive real-world characterization of DDLPS in France, validating known prognostic factors, emphasizing the central role of surgery, and underscoring the persistent and unmet need for more effective systemic therapies.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2026-11-03
DOI
https://doi.org/10.1002/ijc.70747
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France

Axel Le Cesne, Thomas Ryckewaert, Françoise Ducimetière, Matthieu Faron et al.
International Journal of Cancer
Sarcoma Diagnosis and Treatment
article

Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France

Axel Le Cesne, Thomas Ryckewaert, Françoise Ducimetière, Matthieu Faron, Christophe Bouvier, Robin Tranchant, Thibaud Valentin, Sarah Watson, Nelly Firmin, Jean‐Yves Blay, Sixtine De Percin, Julien Bollard, Nicolas Penel, Alice Hervieu, Pascale Dubray‐Longeras, Florence Duffaud, Claire Chemin, Christophe Perrin, Mehdi Brahmi, Emmanuelle Bompas, Maud Toulmonde, Magali Morelle, Christophe Maritaz, Marie Najean
article en

Abstract

Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real-world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry. A total of 1451 adults with histologically confirmed DDLPS diagnosed between 2010 and 2021 across 14 expert centers were included. The median age at diagnosis was 67 years, with a male predominance (M/F ratio 1.84). The retroperitoneum was the most frequent site (51.6%), and tumors were large (median 150 mm) and FNCLCC Grade 2-3 in 82.6%. MDM2 amplification was confirmed in 97.4% of tested cases. Surgery was performed in 91% of localized cases and was the strongest independent prognostic factor for overall survival (OS). After a median follow-up of 78.4 months, median OS was 90.3 months (95% CI 82.7-101.0). Among metastatic patients, the median first-line progression-free survival (PFS1) was 4.1 months, and second-line PFS (PFS2) was 3.1 months, with stable disease as the most common best response (40.6%) and 12% of partial response. Doxorubicin-based chemotherapy remained the predominant systemic treatment but yielded only modest activity, with no difference compared to other regimens in terms of response rate. Independent predictors of improved OS included younger age, smaller tumor size, good performance status, lower grade and absence of metastasis at diagnosis. This large, population-based study provides the most comprehensive real-world characterization of DDLPS in France, validating known prognostic factors, emphasizing the central role of surgery, and underscoring the persistent and unmet need for more effective systemic therapies.

International Journal of Cancer
Centre National de la Recherche Scientifique (FR), Inserm (FR), Université de Montpellier (FR), Aix-Marseille Université (FR), Institut Gustave Roussy (FR), Hôpital Cochin (FR), Centre Georges François Leclerc (FR), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Centre Eugène Marquis (FR), Centre Jean Perrin (FR), Institut Claudius Regaud (FR), Centre Oscar Lambret (FR), Institut Bergonié (FR), Institut de Neurosciences de la Timone (FR), Boehringer Ingelheim (France) (FR), Institut de Recherche en Cancérologie de Montpellier (FR), Hôpital de la Timone (FR), Institut Curie (FR)
Openalex Percentile: Top 13%
Sarcoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon